Background: Management of the axilla in breast cancer patients has evolved from routine axillary lymph node dissection (ALND) for all patients to a highly selective approach based on the assessment of the sentinel lymph nodes (SLNs
tumor spread and potentially prevent death from breast cancer.
Alternatively, the hypothesis by Fisher et al 2, 3 centered on the concept that breast cancer becomes systemic early in its course, although the systemic disease may remain subclinical. Thus, the presence of regional nodal involvement may be a manifestation of metastatic disease elsewhere, and aggressive local tumor control may not affect overall survival. This view represents a pivotal question in breast cancer management. In accepting the latter hypothesis, the surgical management of breast cancer has evolved to develop conservative (less extensive) approaches. Although several groups have reported their experience with "partial mastectomy" or breast-conserving surgery, Fisher et al 4 and Veronesi et al 5 demonstrated that breast-conserving surgery followed by irradiation of the primary tumor was a feasible option for women with early-stage breast cancer in randomized prospective trials. These studies showed that breast-conserving surgery offered patients equivalent long-term survival as traditional mastectomy. 4, 5 Just as the surgical management of the primary tumor has evolved, management of the axilla has evolved as well.
The Changing Role of Axillary Lymph Node Dissection
In 1990, the National Institutes of Health Consensus Conference concluded that the treatment of potentially curable breast cancer should include levels I and II axillary lymph node dissection (ALND). 6 The need for routine ALND was challenged by the introduction of the sentinel lymph node (SLN) biopsy. This concept had a tremendous effect on management of the axilla. In 1994, Giuliano et al 7 demonstrated that the status of the SLN accurately refl ected the status of the entire axillary basin draining a primary breast tumor.
Since these initial reports, the accuracy of SLN surgery has been validated by multiple groups, sparing patients with negative sentinel nodes an ALND and its associated morbidity. 8, 9 Although risks such as lymphedema are present with SLN surgery, the incidence of arm lymphedema is signifi cantly less than with ALND (7% vs 25%). [10] [11] [12] The false-negative rate of SLN biopsy has been demonstrated to be approximately 9.8%, 13 and the rate of locoregional tumor recurrence in patients with negative SLNs who did not have ALND has ranged from 0.1% to 1.5%. [14] [15] [16] [17] Smidt et al 14 evaluated a series of 439 patients with a negative SLN. After a median follow-up of 26 months, axillary tumor recurrence was detected in 2 of 439 patients (0.46%). In addition, a meta-analysis of 3,184 patients with a negative SLN from 13 studies was performed, with a median follow-up of 21 months. Axillary tumor recurrence was detected in 8 of these patients (0.25%). 14 In cases of a positive SLN, standard treatment has been a completion ALND, as outlined by the consensus statement from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). 18, 19 These guidelines stem from a meta-analysis of 69 trials including 8,059 patients who underwent SLN biopsy and subsequent ALND. The results demonstrated that 53% of patients with a positive SLN were found to have disease in non-SLNs. 20 The incidence of non-SLN involvement changes considerably with the extent of disease in the SLN. For patients whose SLN was involved by macrometastatic disease (tumor metastases greater than 2 mm), the incidence of non-SLN involvement is reported to be 40% to 58%. 21 When the SLN is involved by micrometastatic disease (nodal metastasis 0.2 to 2 mm), the incidence of non-SLN involvement is 20%, 22 and in the case of the SLN with isolated tumor cells (≤ 0.2 mm), the incidence decreases to 12%. 23 Factors that infl uence the degree of non-SLN involvement are tumor histology and grade, primary tumor size, multifocality, lymphovascular invasion, estrogen receptor (ER) status, and the ratio of positive SLNs to the total number of sentinel nodes removed. [24] [25] [26] These fi ndings have been important components in the developing trend of forgoing ALND in certain patients, particularly those thought to be at a lower likelihood of having additional disease in the non-SLNs. The American Society of Breast Surgeons issued a consensus statement in 2005 acknowledging this trend 27 : "Outside of clinical trials, usual treatment for SLN-positive patients is a level I-II ALND. However, since axillary node metastases are limited to the SLN in more than half of SLN-positive individuals, there may be low-risk subsets for whom a completion ALND is not required. The decision to omit completion axillary dissection in such a case requires a balanced discussion between the surgeon and the patient regarding the risks of further surgery and any potential for improved outcome with more complete information and/or axillary clearance."
The American College of Surgeons Oncology Group (ACOSOG) Z0011 study 28, 29 was a practicechanging trial that questioned the need for completion ALND in patients with early-stage disease undergoing breast conservation who were found to be SLNpositive. The study concept considered a number of factors, including the overall change in the extent of disease on initial presentation, the changes in the recommendations for adjuvant therapy based more heavily on primary tumor characteristics, and the demonstration of a low incidence of positive non-SLNs. 29 As previously discussed, the SLN has been demonstrated to be the only positive lymph node in many cases. Data from high-volume breast centers indicate that the SLN is the only site of nodal metastasis in 40% to 60% of axillary dissections. 30 Veronesi et al 31 reported on a series of 376 patients who underwent SLN surgery and subsequent ALND. In 73 of 168 patients with a positive SLN (44%), the SLN was the only site of metastatic disease. In a series of 443 patients undergoing SLN and ALND, Krag et al 32 noted a 97% accuracy in identifying the SLNs. In this group, 95 patients had 1 to 3 positive SLNs, and the SLN was the only positive node in 62% of cases. Similarly, Giuliano et al 33 reported a study of 107 patients who underwent SLN surgery and subsequent axillary dissection. Forty-two patients were found to have positive SLNs, and in 67% of cases, the SLN was the only site of metastatic disease.
These fi ndings may refl ect a trend in identifying disease at an earlier stage and therefore at a lower nodal tumor burden. Expanded use of screening and increased awareness of breast cancers have led to a decreased size of primary tumors at presentation. Cady et al 34 reported that the mean maximum diameter of breast cancers at diagnosis was 3 cm from 1979 to 1983 and 2 cm from 1989 to 1993. This downward trend in the size of tumors at presentation, coupled with the high incidence of SLN-only positive axillary disease, suggests that adequate local tumor control and staging in early-stage breast cancer may be accomplished by treating the primary tumor and removing the SLNs.
ALND has been associated with signifi cant morbidity compared with SLN biopsy alone; the risk of lymphedema reported with SLN biopsy is 2% to 7% compared with a lifetime risk of lymphedema with ALND of 25%. 10, 35, 36 Lucci et al 12 compared the postoperative complication rate of women undergoing SLN vs SLN and ALND in the ACOSOG Z0011 study. They found that women in the ALND group had a signifi cantly greater incidence of postoperative complications than did the SLN-only group (70% vs 25%). Complications included wound infection, axillary seromas, axillary paresthesias, brachial plexus injury, and lymphedema. As reported subjectively by study participants, the development of lymphedema was 13% at 1 year in the ALND group vs 2% in the SLN-only group.
Trends to Omit ALND
The use of completion ALND in patients with positive SLNs was decreasing prior to the presentation of the results of the ACOSOG Z0011 trial. This trend was evaluated retrospectively in a number of studies. Bilimoria Similar to the NCDB report, the cohort of patients who underwent SLN biopsy alone in the SEER report were older (59 vs 56 years of age), had a smaller tumor size (16 vs 20 mm), or had lower-grade tumors (21% grade I or II vs 13% grade III). Also, the majority of patients who had SLN biopsy alone underwent breast-conserving surgery (78.8%). This trend may refl ect the increased comfort of physicians to forgo completion ALND in patients who are candidates for postoperative radiotherapy. The authors noted that patients with micrometastasis had no difference in ipsilateral regional events among the groups. Patients with macrometastasis who underwent SLN biopsy with ALND had a lower risk of ipsilateral regional events than did those who underwent SLN biopsy alone (0.08% vs 0.2%; P = .02). However, no significant difference in survival was noted between the two groups at 50 months.
One of the factors that may have infl uenced the decrease in completion ALND for SLN-positive disease after the year 2000 may be the availability of online nomograms to predict non-SLN involvement. Currently, several nomograms have been developed to predict non-SLN involvement for patients with SLN-positive disease. The Memorial Sloan-Kettering Cancer Center (MSKCC) online nomogram, 39 which has been externally validated, is one of the most commonly used. [40] [41] [42] Other available nomograms have been developed at the Mayo Clinic, MD Anderson Cancer Center, and Stanford University. 40, 43, 44 The MSKCC nomogram is an online calculator that provides a risk estimate of non-SLN metastasis based on 9 histopathological vari-ables: frozen section analysis, primary tumor size, primary tumor type (ductal/lobular) and nuclear grade, number of positive SLNs, number of negative SLNs, method of SLN detection (routine hematoxylin and eosin [H&E], serial H&E, or immunohistochemistry [IHC]), presence of lymphovascular invasion, multifocality, and ER positivity (greater than 10%).
Park et al 26 reported on a group of patients from MSKCC in which 1,960 patients with positive SLNs were evaluated from 1997 to 2004. A total of 287 patients (15%) did not undergo completion ALND. In concordance with the aforementioned studies, these patients were older and had more favorable tumors, and the majority underwent breast-conserving therapy. In addition, the median nomogram scores were signifi cantly different between the groups (9% vs 37%), indicating a selection bias in the use of ALND for SLN-positive patients with a higher prediction of non-SLN disease. Eighty-six percent of patients forgoing ALND had nomogram scores of ≤ 20%, whereas 74% of patients undergoing ALND had nomogram scores of > 20%. The 
The Inception of the ACOSOG Z0011 Trial
The aim of the ACOSOG Z0011 study was to examine the impact of ALND on regional control and survival in women with early-stage breast cancer undergoing breast-conserving therapy. The goal was to identify whether ALND can be safely omitted in women with early-stage disease. The hypothesis of the trial was that patients with H&E-detected metastases in the SLN would have similar outcomes with completion ALND and SLN biopsy alone. 28 Eligibility criteria included age older than 18 years and clinical T1 or T2, N0, M0 invasive breast cancer in women electing to undergo breast-conserving surgery. Patients had to have tumors that were 5 cm or smaller on clinical examination and imaging and were clinically node negative (ie, without palpable lymphadenopathy). Patients underwent lumpectomy and SLN biopsy. Those found to have 1 or 2 positive SLNs were randomized to receive either no additional axillary surgery (SLN-only group) or completion ALND (SLN plus ALND group). All patients were required to have negative margins for the lumpectomy specimen and were to undergo whole-breast irradiation following surgery. The trial recommended 45 to 50 Gy of breast radiation, in fractions of 1.8 to 2.0 Gy per day delivered via tangential fi elds without third-fi eld axillary radiation. Patients underwent systemic adjuvant therapy at the discretion of the treating medical oncologist as indicated. Patients excluded from the study were those with known node-positive disease prior to surgery, patients with 3 or more positive nodes, and patients with SLN metastases identifi ed on IHC only.
The trial was activated in May 1999, with a planned target accrual of 1,900 patients. Due to slow accrual and, more importantly, the low event rate in both groups, recruitment was closed in December 2004, with a total of 891 patients enrolled. 28 The number of patients who ultimately received treatment in the study were 388 patients in arm 1 (completion ALND) and 425 patients in arm 2 (SLN alone). Patients were stratifi ed with respect to age (younger or older than 50 years), ER status, and tumor size (< 1 cm, 1 to 2 cm, or > 2 cm). The median age of patients enrolled was 56 and 54 years for arms 1 and 2, respectively. Patients older than 50 years comprised 67.4% of those in arm 1 and 62.6% of those in arm 2. The majority of tumors were T1 (67.1% and 70.5%), infi ltrating ductal type (82.1% and 84%), and ER+ (82.2% and 82.8%) for arms 1 and 2, respectively.
Patients randomized to arm 1 had a median of 17 nodes removed compared with a median of 2 nodes removed in the SLN-only group. The median number of positive nodes in both groups was 1. A total of 41% of SLNs were determined to have micrometastases (≤ 2 mm) or isolated tumor cells. It is important to note the differences in tumor burden between the two groups. The percentage of SLN micrometastasis was 37.5% in the ALND group vs 44.8% in the SLN-only group, with this difference being statistically significant (P = .05). This fi nding suggests that patients in the SLN-only group may have had a more favorable tumor burden. Comparison of the two groups at 6.3 years of follow-up revealed no difference in the rate of axillary tumor recurrence (0.5% vs 0.9% for arms 1 and 2, respectively), in-breast recurrence (3.6% vs 1.9%), or overall locoregional tumor recurrence (4.1% vs 2.8%). The 5-year disease-free survival rates were 82.2% in the ALND group and 83.9% in the SLN-only group, and 5-year overall survival rates were 91.8% and 92.5%, respectively.
By intent-to-treat analysis, adjuvant systemic therapy was delivered to 403 patients in the ALND group (96%) and 423 in the SLN-only arm (97%). Hormonal therapy was given to 195 patients in the ALND group (46.4%) compared with 203 patients in the SLN-only arm (46.6%). Chemotherapy was administered to 243 patients in the ALND arm (57.9%) and 253 patients in the SLN-only arm (58%). Locoregional tumor recurrence was 3.4% in patients who received adjuvant systemic therapy and 3.3% in those who did not.
The trial recommended whole-breast radiation be administered to all patients; however, all patients did not undergo adjuvant radiation therapy. Whole-breast radiation was administered to 88.9% of patients in the ALND group and 89.6% of patients in the SLNonly group. In the group of patients who underwent ALND, 27% had additional nodal metastasis identifi ed on histopathological assessment of the axillary contents. Ten percent of patients with micrometastasis on SLN biopsy who underwent ALND had additional involved nodes removed. We may presume that a similar number of patients in the SLN-only arm had residual non-SLN metastasis. However, this conclusion may not be entirely accurate, as a greater percentage of the SLN-only cohort had micrometastasis and patients with micrometastasis had lower rates of additional nodal metastasis. Failure to stratify patients based on the size of SLN metastasis is a limitation of this trial. The axillary tumor recurrence rate for this arm was less than 1% at 6.3 years. Although subclinical disease may have been treated by adjuvant systemic therapy and irradiation, this fi nding suggests that not all non-SLN metastasis develops into clinically detectable disease. Removing additional involved nodes with an axillary dissection in this group of patients did not improve locoregional tumor recurrence or overall survival.
Supporting Data From Other Clinical Trials
The recently reported update by Galimberti et al 45 of the International Breast Cancer Study Group (IBCSG) trial 23-01 sheds light on the issue of ALND in patients with SLN micrometastasis. The study was a randomized, multicenter, phase III clinical trial comparing axillary dissection with no axillary dissection in patients with micrometastasis in the SLN. A total of 934 patients were randomized: about half to ALND and the other half to SLN only. Patients were clinically node-negative, had a primary tumor < 5 cm, and had a minimal (< 2 mm) tumor burden in 1 to 2 SLNs. The majority of patients (67%) had tumors < 2 cm, and 89% were ER+. Disease-free survival was the study's primary endpoint, and overall survival and systemic disease-free survival were secondary endpoints. The 5-year disease-free survival and overall survival rates in the ALND vs SLN-only groups were 87.3% vs 88.4% (P = .48) and 97.6% vs 98% (P = .35), respectively. Of note, 25% of patients included in this study underwent mastectomy.
The fact that R0 resection to remove all positive lymph nodes may not be required and does not affect overall survival is not a new idea. The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 study provided insight into the natural progression of axillary disease and the clinical consequences of axillary nontreatment. 2 In this study, clinically nodenegative patients were randomized to undergo total mastectomy with ALND (n = 354), total mastectomy with regional irradiation (n = 282), or total mastectomy alone (no treatment to the axilla, n = 344). The total mastectomy-alone arm provides information on the consequences of no treatment to the axilla, neither surgery nor irradiation, and no systemic therapy. Of note, 40% of patients randomized to undergo total mastectomy with axillary dissection were found to have positive axillary lymph nodes on fi nal pathology review. This fi nding indicates that the mastectomy-only arm also had a similarly high percentage of lymphnode positivity, even though they were clinically N0. Of the patients in the mastectomy-only arm, 18.6% presented with clinically palpable axillary nodes on follow-up and underwent delayed ALND. This study result is remarkable in that it is less than half the presumed number of patients with subclinical positive nodes. After assessing for these salvage axillary surgeries, no signifi cant difference in the rates of uncontrolled regional tumor recurrence and overall survival among these clinically node-negative patients was demonstrated, with a 25-year follow-up. 3 These results support Fisher's concept that the biology of breast cancer will dictate its disease progression, as opposed to the mere presence of nodal involvement.
Controversies Surrounding the ACOSOG Z0011 Trial
Several points of debate about the ACOSOG Z0011 trial have been explored: the smaller than anticipated sample size and the low event rate; the older (> 50 years) study population (raising the question of applicability to younger women); the largely ER+ study population (again raising the question of applicability to women with ER-or HER-2+ tumors); the applicability to invasive lobular carcinoma, which comprised a minority of the study cohort; and the length of follow-up.
The planned target accrual for the ACOSOG Z0011 trial was 1,900 patients, as previously mentioned. This number was calculated using a prediction of overall survival rate of 80% at 5 years for women with optimally treated node-positive breast cancer, and clinical noninferiority was defi ned as the SLN-only group having a 5-year survival rate of not less than 75% of that observed in the ALND group. An estimated 500 deaths were needed for the study to have 90% power to confi rm noninferiority of SLN alone compared with ALND.
The fi rst patient was enrolled in May 1999. Due to the low mortality rate observed, the ACOSOG Data and Safety Monitoring Committee closed the study to new patients in December 2004. 28 Even if the trial had accrued the target 1,900 patients, it would have taken more than 20 years of follow-up to observe 500 deaths due to the slower-than-predicted event rate. No preliminary analysis had been performed at the time of closure of the study.
It could be argued that the information obtained from the study is limited, based on a smaller sample size than anticipated and a low event rate. At a median follow-up of 6.3 years, there were 94 deaths: 42 in the SLN-alone group and 52 in the ALND group. Despite the low event rate and signifi cantly lower number of patients enrolled than expected, the study authors maintain that the predefi ned statistical analy-sis plan was able to demonstrate the noninferiority of SLN biopsy alone for overall survival, with a P value of .008. 46 The majority of women in the ACOSOG Z0011 study were older than 50 years. In the multivariate analysis, tumor grade and patient age were associated with locoregional tumor recurrence in either arm. Upon closer evaluation, the majority of locoregional tumor recurrences in young women were in-breast recurrences as opposed to nodal recurrences. 46 In patients younger than age 50, the SLN-only group experienced 5 locoregional recurrence events: 4 in the breast and 1 nodal. The ALND group had 11 locoregional recurrence events: 9 in the breast and 2 nodal.
The tendency of young women to have a higher rate of in-breast tumor recurrence has been demonstrated in previous reports. 47, 48 One retrospective review evaluating 3,064 patients who underwent breast-conserving therapy demonstrated that age < 40 years was an independent risk factor for local tumor recurrence. 48 Based on the fact that the observed locoregional tumor recurrences in women younger than age 50 were primarily breast recurrences as opposed to nodal recurrences, the authors of ACOSOG Z0011 maintain that the study does not provide evidence that young women have a higher rate of nodal tumor recurrence. 46 However, as the majority of women enrolled in the study were older than age 50, the fi ndings may not be widely applicable to younger women.
Another question raised about the ACOSOG Z0011 data is their applicability to subgroups of patients with tumors who are ER-or HER-2/neu+. The development and use of targeted adjuvant endocrine therapy have been demonstrated to signifi cantly reduce the rate of locoregional tumor recurrence as well as improve the rates of disease-free survival and overall survival in women with ER+ tumors. [49] [50] [51] The remarkably low locoregional tumor recurrence rate reported in the ACOSOG Z0011 trial is in part due to the use of targeted adjuvant therapy, which likely treats subclinical disease in the axillary nodal basin. According to the multivariate analysis in the ACOSOG Z0011 trial, there was no difference in the rate of locoregional tumor recurrence in patients who had ER-vs ER+ tumors. However, only 16% of patients in each arm were ER-, which raises the question of whether these results can be extrapolated to patients with ER-disease.
Information with respect to HER-2 status was not included within the study design. When the trial opened in 1999, routine testing of HER-2 was not uniformly practiced. Tumors that express HER-2 tend to be more aggressive. 52 However, patients with HER-2+ tumors may benefi t from the use of targeted adjuvant therapy such as trastuzumab (Herceptin). In randomized controlled trials, the use of adjuvant trastuzumab has been demonstrated to improve the disease-free and overall survival rates in patients with HER-2+ breast cancer.
53,54 Thus, HER-2 positivity may not be a reason to omit or proceed with ALND but rather must be weighed along with the rest of the data available for a patient. 55 The fi ndings of ACOSOG Z0011 may not apply to patients who have not had the benefi t of targeted adjuvant therapy, such as those with triplenegative disease. However, the authors suggest that although the prognosis of patients with triple-negative breast cancer is poor, these tumors are less likely to metastasize to lymph nodes, 56 and thus their prognosis may not rely on a heavy nodal burden. 46 A subset of patients not clearly defi ned in the ACOSOG Z0011 study consists of those with invasive lobular carcinoma. These patients represented only 7% of the trial population. The concern with evaluation of SLNs in patients with lobular histology is that these tumors are more likely to have multiple smaller foci of disease and isolated tumor cells in the SLN, which may not be detected by standard H&E analysis. These nodal metastases may require IHC for detection. 57 Although isolated tumor cells represent a low tumor burden, they may have clinical relevance undetected in this study. This factor must be taken into consideration when evaluating patients with invasive lobular carcinoma with respect to performing ALND. 55 Routine IHC analysis of SLNs has not been supported by ASCO or the College of American Pathologists and was abandoned by many institutions after the data from ACOSOG Z0010 and NSABP B-32 were reported. 13, 35 The ACOSOG Z0010 observational study sought to determine the association between metastases detected by IHC staining of SLNs and bone marrow specimens from patients with early-stage breast cancer and survival. Of the 3,326 SLN specimens that were negative by H&E staining, 10.5% were found to be positive for metastasis on IHC. There was no signifi cant difference in overall survival between patients with IHC-negative disease compared with IHC-positive disease (95.7% vs 95.1%; P =.64). NSABP B-32, which randomized clinically node-negative breast cancer patients to receive SLN alone or SLN plus ALND, identifi ed lymph node metastases by IHC in 15.9% of patients who were SLN-negative on H&E staining. The absolute difference in overall survival between IHC-positive and IHC-negative patients was 1.2% (94.6% vs 95.8%; P = .03).
Another issue regarding the validity of the data from ACOSOG Z0011 is related to the length of followup for the enrolled patients and whether it is adequate for assessing recurrence and survival. 46 We looked at previous studies to answer this question. In NSABP B-04, the median time to axillary tumor recurrence was 14.8 months in clinically node-negative women who did not undergo ALND. At 5 years, the rate of tumor recurrence was 16.2% (55 of 344 patients). On 10-year follow-up evaluation, 75% of patients who remained free of disease at the end of 5 years continued to be free of disease. 58 Similarly, with respect to overall survival, about 75% of patients with negative nodes who were alive at 5 years remained alive at 10 years. Additionally, there was no signifi cant difference between overall survival among the 3 node-negative groups over the entire follow-up. At 10 years, overall survival was 58% for the radical mastectomy group, 59% for patients treated with total mastectomy plus irradiation, and 54% for those undergoing total mastectomy alone. Furthermore, there was no difference in disease-free, distant relapse-free, or overall survival rates among these groups at 25 years.
Greco et al 59 evaluated a series of 401 breast cancer patients prospectively. Patients had tumors up to 3 cm and clinically negative axilla. A total of 383 patients underwent quadrantectomy with no axillary dissection. Of these patients, 67% received postoperative adjuvant radiation therapy. The median time to axillary tumor recurrence was 30.6 months.
Martelli et al 60 reported on a group of 671 patients over the age of 70 with clinically node-negative axilla who underwent breast-conserving therapy with or without axillary dissection (172 patients vs 499 patients). All patients received adjuvant tamoxifen therapy for at least 2 years. The median time from primary surgery to axillary tumor recurrence was 33 months. Upon 15-year follow-up, 90% of patients who developed axillary disease did so within 6 years of surgery. With respect to survival, there was no advantage to axillary dissection in terms of breast cancer mortality.
Grills et al 61 demonstrated that in a group of 568 node-positive, ER+ patients treated with breast-conserving therapy or axillary dissection, with or without nodal irradiation, the incidence of nodal tumor recurrence increased only slightly after 5 years. Thus, based on data available from reported studies, the ACOSOG investigators maintain that a follow-up of 6.3 years is suffi cient to capture the majority of axillary tumor recurrences. 46 
Whole-Breast Radiation Fields and Management of the Axilla
The ACOSOG Z0011 trial recommended whole-breast radiation therapy without the addition of a third fi eld to treat the axilla. The standard technique of wholebreast radiation therapy applied to breast cancer patients following breast-conserving therapy is the two-portal opposed tangential approach. In addition to radiating all the breast tissue, this technique applies radiation to some extent to the low-lying axillary lymph nodes. When treating high-risk patients, some radiation oncologists advocate the use of "high tangential fi elds" to improve axillary coverage. 62 Data from Reznik et al 62 demonstrated that the average doses of radiation delivered to axillary levels 1, 2, and 3 with tangential fi elds are 66%, 44%, and 31% of the prescribed dose, respectively. With these normal tangents, 51% of level 1 and 26% of level 2 axillary nodes receive 95% of the prescribed dose. With minor variation in the fi eld design, radiation can be delivered via high tangential fi elds. This technique achieves almost complete axillary coverage by fi eld edge at least extending the superior fi eld border to within 2 cm of the humeral head and by setting the deep fi eld edge at least 2 cm posterior to the lung/ chest wall interface. 63 In this scenario, 79%, 51%, and 49% of levels I, II, and III receive 95% of the therapeutic dose, respectively.
A limitation of the ACOSOG Z0011 trial is that data concerning features of the fi eld design were not captured for patients enrolled in the study. In addition, all patients did not undergo whole-breast radiation therapy as planned. As previously discussed, 88.9% of patients in the ALND group and 89.6% of patients in the SLN-alone group underwent adjuvant radiation therapy. Due to the potentially therapeutic effect of tangential fi eld radiation on the axilla, the fact that this was not standardized among patients enrolled raises questions regarding the radiation fi elds for these patients. Therefore, when incorporating ACOSOG Z0011 results into clinical practice, radiation oncologists may question whether tangents should be raised to direct radiation to the axilla.
The delivery of radiation to the axilla for treatment of nodal disease is not novel. Gadd et al 64 evaluated the outcome of patients with a positive SLN who underwent axillary radiation therapy in lieu of ALND. The study included 73 patients with clinically T1-2 N0 disease who underwent breast-conserving therapy with a fi nding of a positive SLN. These patients underwent adjuvant axillary radiation therapy as well as systemic therapy. Of the 73 patients, 1.4% developed an axillary tumor recurrence, with a median follow-up of 32 months. Although this study did not compare ALND and axillary radiation therapy, it does suggest that radiation therapy may be an acceptable alternative to ALND in a subset of patients with early-stage disease. However, the data from this study have been published only in abstract format.
This topic is being addressed further in a prospective randomized study by the European Organisation for Research and Treatment of Cancer (EORTC) in the AMAROS (After Mapping of the Axilla: Radiotherapy or Surgery) trial. 65 The AMAROS trial is a phase III study comparing ALND with axillary radiation therapy in patients with proven axillary metastasis by SLN biopsy. The main objective of the trial is to prove equivalent locoregional tumor control and reduced morbidity for axillary radiation therapy. This study will evaluate the axillary recurrence rate as the primary outcome measure. Secondary outcome measures include axillary recurrence-free survival, disease-free survival, overall survival, and qualityof-life measures.
The recently reported results from the NCIC-CTG MA.20 intergroup trial of regional nodal irradiation in early breast cancer have raised the question of additional nodal radiation therapy for high-risk patients undergoing breast-conserving therapy and wholebreast irradiation. 66, 67 The hypothesis for this trial was that adding regional nodal radiation therapy may improve survival compared with breast-alone irradiation after breast-conserving therapy and systemic therapy. The concern with extending the radiation volume is that it may increase the risk of adverse side effects, such as pneumonitis, lymphedema, and cardiac disease (particularly after anthracycline-based chemotherapy). This study included patients who underwent breast-conserving therapy with ALND. Patients were eligible for additional nodal radiation therapy if they had involved nodes. If the nodes were negative, they were eligible if the primary tumor was > 2 cm, if they had < 10 nodes retrieved during ALND, or if they had either grade 3 histology, an ER-tumor, or the presence of lymphovascular tumor invasion. The 1,832 women were randomized to receive either whole-breast and regional nodal radiation therapy or standard whole-breast irradiation. The whole-breast and regional nodal radiation group experienced improved isolated locoregional disease-free survival (96.8% vs 94.5%; P = .02), improved distant disease-free survival (92.4% vs 87.0%; P = .002), and a trend toward improved overall survival (92.3% vs 90.7%; P = .07) at 5 years. The whole-breast and regional nodal irradiation group also experienced an increase in pneumonitis (1.3% vs 0.2%; P = .01) and lymphedema (7.3% vs 4.1%; P = .004) over the standard whole-breast radiation group.
Conclusions
Management of the axilla in breast cancer patients has evolved over the past several decades. We have transitioned from the era of performing routine axillary lymph node dissection (ALND) on all breast cancer patients to identifying patients who need ALND based on results from sentinel lymph node (SLN) biopsy (Table) . In doing so, many patients have been spared the morbidity associated with ALND. Currently, the approach to the axilla has become even more selective, as the choice of ALND may be based not only on the SLN result but also on tumor and patient characteristics. Evaluation of the SLN has also evolved, as data from recent trials support abandoning the routine use of IHC to identify occult metastasis.
The fi ndings from the ACOSOG Z0011 trial are practice-changing, and they evoke the principle demonstrated in NSABP B-04: not all axillary disease becomes clinically detectable or relevant with respect to recurrence and survival. The recurrence and survival rates demonstrated in ACOSOG Z0011 are far superior to those in NSABP B-04, representing the evolution of breast cancer care received by contemporary women. These improved outcomes can be explained by improvements in screening and imaging, which have led to more women presenting with earlier-stage disease. In addition, improved pathological analysis, targeted adjuvant systemic therapy, and radiation therapy have improved locoregional tumor recurrence and overall survival.
Although the fi ndings of ACOSOG Z0011 are impressive, in practice we must remember that the data are applicable to a limited number of cancer patients: those with T1-2 primary tumors with clinically negative axilla and 1 to 2 positive SLN(s) who underwent breast-conserving surgery and adjuvant whole-breast irradiation. The majority of patients were older and had invasive ductal carcinoma, ER+ disease, and a low nodal tumor volume. This patient cohort does not represent the breadth of patients who present with breast cancer. Surgeons must use discretion when applying these data to younger patients or to those with invasive lobular carcinoma, ER-, and HER-2+ disease. The trial did not address (and therefore should not be translated to) patients with early-stage disease who elect mastectomy, patients undergoing neoadjuvant chemotherapy, or patients who may be receiving partial-breast radiation therapy, intraoperative radiation therapy, or whole-breast irradiation in the prone position. 68 Additionally, these data cannot be extrapolated to advise axillary radiation therapy in lieu of ALND. For patients with known positive lymph node metastasis preoperatively, those with palpable adenopathy, and those with more than 2 positive SLNs or lymph nodes with extracapsular tumor extension, ALND should be recommended.
Although nodal staging has become less invasive for more women, ALND still plays an important role for regional tumor control and staging for many breast cancer patients. As the understanding of breast cancer biology deepens and adjuvant therapies become more effective, more individualized treatment via a multidisciplinary approach is possible. Important questions with regard to management of the axilla in additional subsets of patients may be answered in the future, with the next generation of trials. These trials may include patients undergoing mastectomy, neoadjuvant chemotherapy, axillary radiation therapy, or partial-breast irradiation.
